Keith Kaye MD
Professor, Internal Medicine, Wayne State University SOM
Join to view full profile
1500 East Medical Center DriveAnn Arbor, MI 48109
Phone+1 313-745-7105
Fax+1 313-993-0302
Dr. Kaye is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Infectious Disease, 1997 - 2000- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1994 - 1997
Perelman School of Medicine at the University of PennsylvaniaClass of 1994
Certifications & Licensure
NJ State Medical License 2021 - 2027
MI State Medical License 2008 - 2024
NC State Medical License 2000 - 2009
American Board of Internal Medicine Infectious Disease
Clinical Trials
- Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME) Start of enrollment: 2012 Oct 06
- Optimizing Clinical Use of Polymyxin B
- Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection Start of enrollment: 2017 Jul 07
Publications & Presentations
PubMed
- Threats to Success in Infection Prevention and Control in Healthcare Settings: Device and Pathogen Management.Keith S Kaye, Sorabh Dhar
Infectious Disease Clinics of North America. 2026-09-01 - Systems-Level Phosphoproteomic and RPPA Profiling Reveals Stress and DNA Damage Signalling as Early Drivers of Polymyxin B Neurotoxicity.Maytham Hussein, Thuraya Safaa Ansaf, Terry C C Lim Kam Sian, Mark Baker, Pouya Faridi
Molecular Neurobiology. 2026-08-14 - Gram-negative bacterial infection randomized controlled trials (RCTs) in the 21st century: characteristics and evolution.Fabian Patauner, Hyeri Seok, Navaneeth Narayanan, Jason M Pogue, Emanuele Durante-Mangoni
JAC-Antimicrobial Resistance. 2026-08-01
Journal Articles
- Epidemiology of Diabetic Foot Infection in the Metro-Detroit Area with a Focus on Independent Predictors for Pathogens Resistant to Recommended Empiric Antimicrobial T...Keith S Kaye, Paul E Kilgore, Kathryn Deeds, Rahul Pansare, Sorabh Dhar, Open Forum Infectious Diseases
- Ceftazidime/avibactam, Meropenem/vaborbactam or Both? Clinical and Formulary ConsiderationsRobert A Bonomo, Keith S Kaye, Clinical Infectious Diseases
Lectures
- Internal Medicine Update: Inpatient & Outpatient Care for the Hospitalist & PCPAmerican Medical Seminars, Inc., Sarasota, Florida - 11/21/2011
- A Systematic Review and Meta-analysis of the Association between Hyperglycemia and Surgical Site InfectionsDetroit, MI - 6/15/2014
Other
- Infections and antimicrobial resistance in the intensive care unitKaye K, Marchaim D
http://www.uptodate.com/contents/infections-and-antimicrobial-resistance-in-the-intensive-care-unit
UpToDate, Wolters Kluwer Health - 2012-10-03
Press Mentions
FDA Approves Zaynich for cUTIJune 1st, 2026- Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in the Lancet Infectious DiseasesMay 11th, 2023
- FAQs: Improving Empiric Antibiotic Regimens for HABP/VABP in the ICUDecember 6th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: